KonstantinDobrenkovMD

PubMed

• 5 citations
  Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
  Lars Guelen, Thierry O Fischmann, Jerelyn Wong, Smita Mauze, Marco Guadagnoli, Nikolina Bąbała, Jozef Wagenaars, Veronica Juan, David Rosen, Winnie Prosise, Maurice Ha...> ;Journal for Immunotherapy of Cancer. 2022 Sep 1
• 8 citations
  Introducing a new reporter gene, membrane-anchored Cypridina luciferase, for multiplex bioluminescence imaging
  Maxim A. Moroz, Juan Zurita, Anna Moroz, Ekaterina Nikolov, Yury Likar, Konstantin Dobrenkov, Jason T. Lee, Larissa Shenker, Ronald G. Blasberg, Inna Serganova, Vladim...> ;Molecular Therapy Oncolytics. 2021 Jun 25
• 22 citations
  Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
  Kyriakos P. Papadopoulos, Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen, Richard Wnek, Georgina V. Long> ;Clinical Cancer Research. 2021 Apr 1
• 34 citations
  First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizuma...
  Ravit Geva, Mark Voskoboynik, Konstantin Dobrenkov, Kapil Mayawala, Jennifer Gwo, Richard Wnek, Elliot Chartash, Georgina V. Long> ;Cancer. 2020 Nov 15
• 27 citations
  Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
  Sayed Shahabuddin Hoseini, Konstantin Dobrenkov, Dmitry Pankov, Xiaoliang L. Xu, Nai-Kong V. Cheung> ;Oncoimmunology. 2017 Apr 28
• 91 citations
  Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults
  Konstantin Dobrenkov, Irina Ostrovnaya, Jessie Gu, Irene Y. Cheung, Nai-Kong V. Cheung> ;Pediatric Blood & Cancer. 2016 Jun 15
• 58 citations
  GD2-Targeted Immunotherapy and Radioimmunotherapy
  Konstantin Dobrenkov, Nai-Kong V. Cheung> ;Seminars in Oncology. 2014 Oct 1
• Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.
  Benezra, M., Phillips, E., Tilki, D., Ding, B. S., Butler, J., Dobrenkov, K., Siim, B., Chaplin, D., Rafii, S., Rabbany, S., Bradbury, M. S.> ;Leukemia. 2012 Aug
• 67 citations
  Monitoring the Efficacy of Adoptively Transferred Prostate Cancer–Targeted Human T Lymphocytes with PET and Bioluminescence Imaging
  Konstantin Dobrenkov, Malgorzata Olszewska, Yury Likar, Larissa Shenker, Gertrude Gunset, Shangde Cai, Nagavarakishore Pillarsetty, Hedvig Hricak, Michel Sadelain, Vla...> ;Journal of Nuclear Medicine. 2008 Jul 1
• 220 citations
  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
  Matthias Stephan, Vladimir Ponomarev, Renier J. Brentjens, Alex H Chang, Konstantin Dobrenkov, Glenn Heller, Michel Sadelain> ;Nature Medicine. 2007 Nov 18
• Registration of planar bioluminescence to magnetic resonance and x-ray computed tomography images as a platform for the development of bioluminescence tomography recon...
  Beattie, B. J., Klose, A. D., Le, C. H., Longo, V. A., Dobrenkov, K., Vider, J., Koutcher, J. A., Blasberg, R. G.> ;J Biomed Opt. 2009 Mar 01
• Join now to see all